Avalo Therapeutics ($AVTX) Insider Trading & Smart Money Activity
Avalo Therapeutics, Inc. ($AVTX) has 4 insider trades, 4 13F position changes and 1 analyst rating on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($202.44K), net -$202.44K.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 1
- Net insider $ (12 mo)
- -$202.44K
- Congress trades (12 mo)
- 0
- 13F moves on file
- 4
- Analyst ratings on file
- 1
AVTX insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 3 / 1 |
| Q3 2026 | 0 | 1 · $202.44K | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All AVTX insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Sullivan Christopher RyanChief Financial Officer | Sell (Open-market sale) 10b5-1 | 12.39K sh | $202.44K | -7.7% | -32.0% | — | ||||
| Insider | Ron Philip | Buy (Grant or award) | 40.20K sh | +3.6% | -0.4% | Read | |||||
| Insider | Mittie DoyleChief Medical Officer | Sell (Option exercise) | 1.45K sh | +3.6% | -0.4% | — | |||||
| Insider | Mittie DoyleChief Medical Officer | Buy (Option exercise) | 1.45K sh | $11.66K | +3.6% | -0.4% | Read | ||||
| Analyst | B of A Securities | Reiterates to buy | PT $35 | +15.7% | +28.1% | Read | |||||
| 13F | Rtw Investments | New | +856.96K sh | $15.84M | -7.8% | -17.7% | Read | ||||
| 13F | Caption Management | Added | +402.36K sh | $8.41M | -7.8% | -17.7% | Read | ||||
| 13F | Avoro Capital Advisors | New | +1.41M sh | $26.06M | -7.8% | -17.7% | Read | ||||
| 13F | Belvedere Trading | Sold out | -4.53K sh | -18.4% | -31.4% | — |
1W / 1M / 6M = how AVTX moved from the trade or filing date.
Insider trading in AVTX: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer | 1 | -$202.44K | Sep 16, 2026 | |
| Mittie Doyle | Chief Medical Officer | 2 | — | Jun 23, 2026 | |
| Ron Philip | 1 | — | Jun 23, 2026 |
Institutions moving AVTX (13F)
Analyst ratings on AVTX
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| B of A Securities | Reiterates | buy | $35 | +15.7% | +28.1% | Read |
Frequently asked questions
Are AVTX insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 1 open-market sale worth $202.44K, a net -$202.44K.
What is the latest insider trade in AVTX?
Sullivan Christopher Ryan, Chief Financial Officer filed a sell (open-market sale) of 12.39K sh worth $202.44K on Sep 16, 2026.
Which institutions changed their AVTX positions?
Recent 13F filers moving the stock include Rtw Investments, Caption Management, Avoro Capital Advisors and Belvedere Trading.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.